Log in or Sign up for Free to view tailored content for your specialty!
Rheumatoid Arthritis News
Medicare price negotiation list includes rheumatology drugs ustekinumab, etanercept
The first 10 drugs eligible for price negotiation through Medicare includes etanercept and ustekinumab, biologic therapies commonly used to treat patients with rheumatic diseases, the Biden administration announced.
First 10 drugs chosen for Medicare price negotiations
HHS announced the first 10 drugs that will be subject to Medicare price negotiations.
Log in or Sign up for Free to view tailored content for your specialty!
Biosimilar TNF inhibitors led to reduced prices, no increase in availability in Poland
The emergence of biosimilar TNF inhibitors in Poland led to reduced prices and expenditures, but little improvements in treatment availability, according to data published in Annals of the Rheumatic Diseases.
Rheumatologists must be ‘more proactive’ in response to patients losing abortion access
Following last year’s U.S. Supreme Court’s decision overturning federal abortion protections, rheumatologists must change their practice with regard managing patients’ reproductive health, said presenter at the 2023 AWIR annual conference.
‘We are rarely documenting contraception’: Rheumatologists can improve pregnancy planning
Rheumatologists can help patients with lupus and other rheumatic diseases avoid potentially dangerous unintended pregnancies by regularly documenting their contraception use, according to a presenter at the 2023 AWIR annual conference.
Low-dose glucocorticoids for rheumatoid arthritis lead to small weight gain
When taken over 2 years for rheumatoid arthritis, low-dose glucocorticoids were associated with slight weight gain, but they did not significantly affect BP, according to research published in Annals of Internal Medicine.
‘Lipid paradox’ may obscure cardiovascular risk in patients with inflammatory disease
AUSTIN, Texas — Providers should carefully consider the “lipid paradox” when monitoring cardiovascular risks in patients with rheumatic inflammatory diseases, noted a presenter at the 2023 Rheumatology Nurses Society annual conference.
Adalimumab biosimilar achieves pharmacokinetic similarity in interchangeability study
The adalimumab biosimilar Hadlima achieved its pharmacokinetic similarity endpoints in a phase 4 interchangeability study, according to a press release from the manufacturer.
Rheumatology, pulmonology must support each other in managing interstitial lung disease
AUSTIN, Texas — Ongoing communication between rheumatology and pulmonology is essential to managing “unpredictable” interstitial lung disease, according to a presenter at the 2023 Rheumatology Nurses Society annual conference.
FDA grants competitive generic therapy approval for indomethacin suppositories
The FDA has granted final approval to Zydus Lifesciences to manufacture and market generic indomethacin 50 mg suppositories, according to a company press release.
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read